Prio Wealth Limited Partnership Sells 29,019 Shares of Boston Scientific Co. (NYSE:BSX)

Prio Wealth Limited Partnership trimmed its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 3.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 725,424 shares of the medical equipment provider’s stock after selling 29,019 shares during the quarter. Boston Scientific makes up about 1.8% of Prio Wealth Limited Partnership’s investment portfolio, making the stock its 13th largest holding. Prio Wealth Limited Partnership’s holdings in Boston Scientific were worth $60,791,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in BSX. Eagle Bay Advisors LLC grew its position in Boston Scientific by 542.1% during the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 309 shares during the period. First Foundation Advisors bought a new position in shares of Boston Scientific in the first quarter worth approximately $25,000. Triad Wealth Partners LLC bought a new position in shares of Boston Scientific in the second quarter worth approximately $26,000. Andra AP fonden bought a new position in shares of Boston Scientific in the second quarter worth approximately $29,000. Finally, RiverPark Advisors LLC bought a new position in shares of Boston Scientific during the first quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BSX. TD Cowen upped their target price on shares of Boston Scientific from $86.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft upped their target price on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. BTIG Research upped their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. JPMorgan Chase & Co. upped their target price on shares of Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Finally, Needham & Company LLC lowered shares of Boston Scientific from a “buy” rating to a “hold” rating and set a $86.00 target price for the company. in a research report on Friday. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $90.24.

Boston Scientific Trading Up 0.5 %

BSX stock traded up $0.48 during trading on Monday, hitting $88.55. The company had a trading volume of 1,580,801 shares, compared to its average volume of 5,935,764. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52-week low of $49.15 and a 52-week high of $88.79. The company has a 50 day simple moving average of $82.49 and a 200-day simple moving average of $77.22. The firm has a market capitalization of $129.91 billion, a P/E ratio of 74.66, a PEG ratio of 2.87 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same period in the prior year, the business earned $0.53 EPS. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. As a group, research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the sale, the executive vice president now directly owns 40,188 shares in the company, valued at approximately $2,978,734.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares in the company, valued at $133,046,484.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 316,253 shares of company stock worth $26,714,298 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.